Watch DAY 1 of our 2020 virtual conference here:    • 2020 Prostate Cancer Patient Conferen...   (featuring Daniel Margolis, MD on prostate imaging and Laurence Klotz, MD on active surveillance)

Watch DAY 2 here:    • 2020 Prostate Cancer Patient Conferen...   (featuring Nicholas J. Vogelzang, MD, FASCO, FACP on treatments for advanced prostate cancer and Mack Roach, MD on radiation treatments)

Public health expert and PCRI moderator, Mark Moyad, MD, MPH, asks medical oncologist, Evan Yu, MD, about the role of cytotoxic chemotherapy in the optimal treatment of prostate cancer as of 2020 and into the near future.

0:09 Dr. Moyad asks Dr. Yu why chemotherapy is still so prevalent in the treatment of prostate cancer despite being perceived as archaic, and he asks Dr. Yu to describe the scenarios in which he would consider chemotherapy for a patient.

1:10 Dr. Yu defines chemotherapy and specifies that oncologists use the word to describe cytotoxic chemotherapies that poison rapidly dividing cells.

2:15 Dr. Yu posits that cytotoxic chemotherapies are unpopular because they are non-specific and attack all rapidly dividing cells. There is a desire to get more specific, perhaps genetically targets medicines.

2:35 Dr. Yu argues that cytotoxic chemotherapies still have an important role in prostate cancer.

3:22 Dr. Moyad asks Dr. Yu about sequencing (the order in which medicines are used) Taxotere and Jevtana, the two cytotoxic chemotherapies approved for prostate cancer. He also asks about other chemotherapies not yet approved for the treatment of prostate cancer, but still sometimtes used (e.g. Carboplatin).

Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org

To learn more about prostate cancer visit http://www.pcri.org

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#ProstateCancer #MarkMoyadMD #EvanYuMD